Latest News & Features
Biotechnology
A court has rejected Gilead’s attempt to overturn a $752 million verdict in a patent dispute with BMS’ Juno Therapeutics over CAR-T therapies. 2 April 2020
Biotechnology
IP law firm EIP has enhanced its life science capabilities with the addition of Monika Rai as a partner. 2 April 2020
Big Pharma
Almost 150 health and poverty activist campaigns, including Médecins Sans Frontières, have urged Gilead Sciences to waive patent and exclusivity rights for potential COVID-19 treatment remdesivir. 2 April 2020
Americas
A US judge has opened the door to generic versions of heart disease drug Vascepa, after invalidating Amarin’s key patents covering the drug. 1 April 2020
Big Pharma
Gilead Sciences says it is expanding access to its experimental antiviral remdesivir for treatment of COVID-19, albeit on a limited basis. 31 March 2020
Americas
Jonathan Tietz, Jason Mock, and Kristel Schorr of Foley & Lardner offer their thoughts on patent procurement and licensing for COVID-19-related technologies. 31 March 2020
Americas
Numerous associations and individuals have come together to ask the World Health Organization to build a global pool for IP rights related to the COVID-19 pandemic. 31 March 2020
Big Pharma
Canada is the latest country to adopt emergency measures in order to secure drugs and medical equipment in the fight against COVID-19. 27 March 2020
Americas
A consortium of life sciences companies including Novartis, Bristol Myers Squibb and GSK have united to accelerate the development, manufacture and delivery of vaccines, diagnostics, and treatments for COVID-19. 27 March 2020
Big Pharma
Gilead Sciences has agreed to drop the lucrative “orphan drug” designation for an antiviral touted as a potential coronavirus treatment, after criticism from activists and politicians including Bernie Sanders. 26 March 2020